You Deserve the Most Accurate Autoimmune Testing Available
You Deserve The Most Accurate Autoimmune Testing Available
AVISE Rheumatology Testing is the Most Accurate Solution for Actionable Results.
Backed by science and evidence, AVISE Lupus powered by CB-CAPs, has been shown to increase physician conﬁdence in both ruling in and ruling out SLE, leading to treatment initiation in positive patients and higher patient-reported outcomes.
Increased odds for SLE diagnosis when AVISE Lupus is positive and anti-dsDNA is negative.
Costs for diagnostic tests decrease twice as much compared to patients tested with General Reference Lab tests in the year following AVISE or General Reference Lab testing.
Increased odds of initiation when AVISE is positive and anti-dsDNA negative.
$2,000 in savings per eligible patient.
Manage every step of your patient’s lupus journey with the AVISE® complete portfolio of tests
Diagnose the right autoimmune disease with confidence
Prognose which organs may be under attack
Monitor disease progression with unique serological markers
When you need accuracy, you need AVISE testing
Ramsey-Goldman R, Alexander RV, Massarotti EM, Wallace DJ, Narain S, Arriens C, Collins CE, Saxena A, Putterman C, Kalunian KC, O'Malley T, Dervieux T, Weinstein A. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020 Jan;72(1):78-88. doi: 10.1002/art.41093. Epub 2019 Nov 25. PMID: 31469249; PMCID: PMC6972605.
Wallace DJ, Silverman SL, Conklin J, Barken D, Dervieux T. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products. Lupus Sci Med. 2016 Feb 1;3(1):e000127. doi: 10.1136/lupus-2015-000127. PMID: 26870391; PMCID: PMC4746498.
Alexander RV, Rey DS, Conklin J, Domingues V, Ahmed M, Qureshi J, Weinstein A. A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus. . Lupus Sci Med. 2021 Jul;8(1):e000528. doi: 10.1136/lupus-2021-000528. PMID: 34253650; PMCID: PMC8276296.
Liang E, Taylor M, McMahon M. Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression. . Lupus Sci Med. 2020 Mar 18;7(1):e000345. doi: 10.1136/lupus-2019-000345. PMID: 32231785; PMCID: PMC7101049.
Wallace DJ, Alexander RV, O'Malley T, Khosroshahi A, Hojjati M, Loupasakis K, Alper J, Sherrer Y, Fondal M, Kataria R, Powell T, Ibarra C, Narain S, Massarotti E, Weinstein A, Dervieux T. Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. Lupus Sci Med. 2019 Sep 19;6(1):e000349. doi: 10.1136/lupus-2019-000349. PMID: 31592328; PMCID: PMC6762037.
Mossell J, Goldman JA, Barken D, Alexander RV. The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus. Open Rheumatol J. 2016 Oct 31;10:71-80. doi: 10.2174/1874312901610010071. PMID: 27867431; PMCID: PMC5101629.
Take control over your patient’s autoimmune disease.
Request a Consultation
Would you like to learn more about AVISE testing or request a technical consultation about a test report?
Contact us using the form below and a representative will contact you shortly.